Compare Cassava Sciences Inc (FLNA) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Altria Group Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Altria Group Inc trades at $71.31 (market cap $115.85B). The key difference: Altria Group Inc is far larger — about 2940.4× Cassava Sciences Inc's market cap, and Altria Group Inc pays a 6.4% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Altria Group Inc for 154 Days on average.
| FLNA | MO | |
|---|---|---|
Market Cap | $39.40M | $115.85B |
Volume | 759,018 | 6,934,962 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $74.92 |
52-Week Low | $0.68 | $54.72 |
Typical Hold Time | 37 Days | 154 Days |
Enterprise Value | -$43.28M | $138.06B |
Dividend Yield | — | 6.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
